Matt Sause & Roche

Matt Sause: Matt Sause, CEO of Roche Diagnostics, provided commentary on the disruptive potential of the AXELIOS 1 platform for the sequencing community and personalized healthcare.

Roche: Roche launched its new AXELIOS 1 sequencing platform, which is expected to enhance its position in the genomics market and potentially drive future revenue growth.

Matt Sause: As CEO of Roche Diagnostics, Matt Sause announced the product launch, underscoring Roche's commitment to liver disease diagnostics.

Roche: Roche introduced the cobas HDV test, expanding its diagnostics offering and reinforcing its leadership in automated molecular testing. The launch may drive incremental revenue and strengthen customer loyalty.

Matt Sause: As CEO of Roche, Matt Sause announced the CE Mark and highlighted the test's role in advancing TB elimination.

Roche: Roche received CE Mark for its Elecsys IGRA TB test, expanding its diagnostics offering and potentially boosting sales in TB testing.

Matt Sause: Matt Sause, CEO of Roche Diagnostics, commented on the significance of the FDA approval for providing new therapeutic options for prostate cancer patients.